Innovation1 Biotech Inc. carries a market capitalization of 4,494.00, placing it among publicly traded companies globally. Its enterprise value stands at 974,329.21, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4,494.00 |
| Enterprise Value | 974,329.21 |
Innovation1 Biotech Inc. currently has 22.47M shares outstanding.
| Shares Outstanding | 22.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.14 |
| P/FCF Ratio | -0.91 |
| P/OCF Ratio | -0.91 |
Innovation1 Biotech Inc. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -18.13, indicating conservative leverage, while an interest coverage ratio of -1.51 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.04 |
| Quick Ratio | 0.04 |
| Debt / Equity | -18.13 |
| Debt / EBITDA | -0.88 |
| Interest Coverage | -1.51 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -267.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Innovation1 Biotech Inc.'s stock has gained approximately 0.0000025% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.0000025% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
EBITDA reached -687,353.00, while operating income came in at -688,400.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -688,400.00 |
| Pretax Income | -5.30M |
| Net Income | -5.30M |
| EBITDA | -687,353.00 |
| EBIT | -688,400.00 |
| Earnings Per Share (EPS) | -0.25 |
Innovation1 Biotech Inc. holds 107,527.00 in cash and equivalents against 605,062.00 in total debt, resulting in a net debt position of 497,535.00. Total book value stands at -59.55M, with working capital of -2.79M providing operational flexibility.
| Cash & Cash Equivalents | 107,527.00 |
| Total Debt | 605,062.00 |
| Net Debt | 497,535.00 |
| Equity (Book Value) | -59.55M |
| Book Value Per Share | -2.80 |
| Working Capital | -2.79M |
Innovation1 Biotech Inc. produced -515,397.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -515,397.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -515,397.00 |
| FCF Per Share | -0.02 |
The company's payout ratio of 14.71 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 14.71 |
| Shareholder Yield | -121.71 |
| FCF Yield | -109.96 |
Innovation1 Biotech Inc.'s most recent stock split took place on January 14, 2021 with a 308:1 split ratio.
| Last Split Date | 1/14/2021 |
| Split Ratio | 308:1 |
Innovation1 Biotech Inc. posts an Altman Z-Score of -742.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -742.78 |